Selective adrenergic uptake inhibitor - Neurocrine

Drug Profile

Selective adrenergic uptake inhibitor - Neurocrine

Alternative Names: Selective norepinephrine reuptake inhibitor - Neurocrine; sNRI - Neurocrine Biosciences

Latest Information Update: 28 Feb 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Neurocrine Biosciences
  • Class
  • Mechanism of Action Adrenergic uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Neuropathic pain; Psychiatric disorders; Urinary incontinence

Most Recent Events

  • 05 Feb 2008 Discontinued - Phase-I for Neuropathic pain in USA (unspecified route)
  • 05 Feb 2008 Discontinued - Phase-I for Psychiatric disorders in USA (unspecified route)
  • 05 Feb 2008 Discontinued for Urinary incontinence in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top